63720-50-3 Usage
Uses
Used in Organic Synthesis:
Ethanone, 2-(4-methoxyphenyl)-1-[3-(phenylmethoxy)phenyl]is utilized as a key intermediate in the synthesis of various organic compounds. Its complex structure allows for the creation of a wide range of molecules with potential applications in different industries.
Used in Medicinal Chemistry:
In the pharmaceutical industry, Ethanone, 2-(4-methoxyphenyl)-1-[3-(phenylmethoxy)phenyl]is employed as a building block for the development of new drugs and bioactive compounds. Its unique properties contribute to the design and synthesis of molecules with potential therapeutic effects.
Used in Drug Discovery and Development:
Ethanone, 2-(4-methoxyphenyl)-1-[3-(phenylmethoxy)phenyl]is used as a valuable tool in drug discovery and development. Its structure and properties facilitate the identification and optimization of potential drug candidates, leading to the creation of novel therapeutic agents.
Used in Chemical Reactions and Mechanisms Study:
In the field of chemistry, Ethanone, 2-(4-methoxyphenyl)-1-[3-(phenylmethoxy)phenyl]is used to study chemical reactions and mechanisms. Its complex structure provides insights into the behavior of molecules during various chemical processes, contributing to a deeper understanding of chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 63720-50-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,3,7,2 and 0 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 63720-50:
(7*6)+(6*3)+(5*7)+(4*2)+(3*0)+(2*5)+(1*0)=113
113 % 10 = 3
So 63720-50-3 is a valid CAS Registry Number.
63720-50-3Relevant academic research and scientific papers
Selective endothelin A receptor antagonists. 2. Discovery and structure-activity relationships of 5-ketopentanoic acid derivatives
Astles,Brown,Harris,Harper,McCarthy,Porter,Smith,Walsh
, p. 515 - 522 (2007/10/03)
The second in this series of papers describes the further progress made in the discovery of a potent and selective endothelin ET(A) receptor antagonist for the potential treatment of diseases in which endothelin has been shown to have a pathophysiological role including hypertension, ischaemic diseases and atherosclerosis. We describe herein the synthesis and structure-activity relationships of a novel series of 5-ketopentanoic acid derivatives exemplified by the lead compound 1 (IC50 0.72 μM, rat aortic ET(A)R). Optimisation of the in vitro binding of 1 led to the identification of a more potent compound (37) which exhibited an IC50 300-fold selectivity for the ET(A) receptor over the ET(B) receptor. This compound demonstrated functional antagonism of endothelin-induced vasoconstriction in vitro.
